The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent

Chloé Grasselly, Morgane Denis, Aurore Bourguignon, Nolan Talhi, Doriane Mathe, Anne Tourette, Laurent Serre, Lars Petter Jordheim, Eva Laure Matera and Charles Dumontet

Abstract

Grasselly C Frontiers in Immunology 2018

more

Synthesis and Preclinical Evaluation of TPA-Based Zinc Chelators as Metallo-beta-lactamase Inhibitors

Christian Schnaars, Geir Kildahl-Andersen, Anthony Prandina, Roya Popal†, Sylvie Radix, Marc Le Borgne , Tor Gjøen, Adriana Magalhães Santos Andresen, Adam Heikal, Ole Andreas Økstad, Christopher Fröhlich, Ørjan Samuelsen, Silje Lauksund, Lars Petter Jordheim, Pål Rongved, and Ove Alexander Høgmoen Åstrand

Abstract

Schnaars C 2018 ACS Inf Dis

more

Esophageal cancer cells resistant to T-DM1 display alterations in cell adhesion and the prostaglandin pathway

Juliette Sauveur, Eva-Laure Matera, Kamel Chettab, Philippe Valet, Jerome Guitton, Ariel Savina, and Charles Dumontet

Abstract

Sauveur J Oncotarget 2018

more

Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodies.

Duong, M. N., Matera, E., Mathe, D., Evesque, A., Valsesia-Wittmann, S., Clemenceau, B., and Dumontet, C

Abstract

Duong M mAbs 2015

more

Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models

Herter, S., Herting, F., Mundigl, O., Waldhauer, I., Weinzierl, T., Fauti, T., Muth, G., Ziegler-Landesberger, D., Van Puijenbroek, E., Lang, S., Duong, M. N., Reslan, L., Gerdes, C. A., Friess, T., Baer, U., Burtscher, H., Weidner, M., Dumontet, C., Umana, P., Niederfellner, G., Bacac, M., and Klein, C

Abstract

Herter S Molecular Cancer Therapeutics 2013

more